Tumor-Infiltrating Lymphocyte Therapy After Immunotherapy in Advanced Melanoma: Omid Hamid, MD

Video

The director of the Melanoma Program at Cedars-Sinai Medical Center discussed the efficacy of TIL therapy following immunotherapy in advanced melanoma.

This content originally appeared on our sister site, OncLive.

OncLive spoke with Omid Hamid, MD, director, Melanoma Program, Cedars-Sinai Medical Center, chief, Translational Research and Immunotherapy, director, Melanoma Therapeutics, Phase I Immuno-Oncology Program, The Angeles Clinic and Research Institute, to learn more about the efficacy of tumor-infiltrating lymphocyte (TIL) therapy following immunotherapy in advanced melanoma.

Lessons are continuing to be learned regarding TIL therapy in melanoma as more data emerge from large clinical trials. Hamid discussed how TIL therapy can be given in any type of hospital setting, meaning it is not limited to academic centers that have facilities where TILs can be manufactured. Many centers have been able to utilize TILs with the help of newer companies that make the therapies off site, Hamid added.

Moreover, it was discovered that in patients who are resistant to other types of immunotherapies, such as checkpoint inhibitors, TIL therapy can induce durable responses, Hamid continued. Data that have been recently presented demonstrated that approximately 80% of patients responding to TIL therapy were those whose best response to checkpoint inhibition with PD-1 inhibitors was progressive disease, Hamid explains. Additionally, patients who previously benefited from anti­–CTLA-4 therapy have the potential to benefit from this therapy as well, Hamid says.

Overall, these data suggest that adoptive T-cell therapy could become a standard in the care option for patients with metastatic melanoma, Hamid concluded.

Recent Videos
Nirav Shah, MD, MSHP, associate professor of medicine, at the Medical College of Wisconsin
Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center
Reena Sharma, MD, an adult metabolic consultant at Salford Royal Hospital
Mark Hamilton, MD, PhD, a hematology-oncology and bone marrow transplant (BMT) cell therapy fellow at Stanford University
Barry J Byrne, MD, PhD, the chief medical advisor of MDA and a physician-scientist at the University of Florida
Barry J Byrne, MD, PhD, the chief medical advisor of MDA and a physician-scientist at the University of Florida
Sarah Larson, MD, the medical director of the Immune Effector Cell Therapy Program in the Division of Hematology/Oncology at David Geffen School of Medicine at University of California, Los Angeles (UCLA)
David Porter, MD, the director of cell therapy and transplant at Penn Medicine
David Porter, MD, the director of cell therapy and transplant at Penn Medicine
Georg Schett, MD, vice president research and chair of internal medicine at the University of Erlangen – Nuremberg
Related Content
© 2025 MJH Life Sciences

All rights reserved.